MNI forms promising Open Science partnership with Takeda


A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.

The Neuro to create world’s first ALS Phase 1 clinical trial unit

In Focus

A generous donation by the Tenaquip Foundation will improve the quality of care available to ALS patients at The Neuro, and increase the rate at which researchers can evaluate new ALS drugs.

MNI scientists receive major funding for ALS research


Researchers at the Montreal Neurological Institute who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23, by the ALS Society of Canada in partnership with Brain Canada.